General
New FDA deal keeps Gilead drug competitive with AstraZeneca and Daiichi in breast cancer treatment – MedCity News
The FDA has expanded approval of a targeted therapy from Gilead Sciences as a new first-line treatment for triple-negative breast...
Read moreDetails
Prayer to Overcome Self-Pity | Daily prayer for June 25
A prayer to free yourself from the grip of self-pityBy Kelly BalarieBible reading:“Then Jesus said to him, “Get up! Take...
Read moreDetails
Second worker dies at Hungarian BYD factory, already under scrutiny for its work practices
Szeged Mayor Laszlo Botka C visits BYD's new energy passenger vehicle factory in Szeged, Hungary, April 21, 2026. (Photo by...
Read moreDetails
The World Cup unites cultures in a festival of color and passion
FOLLOWINGMexico perfect, Brazil leads and Morocco returns on the third date of the World Cup04:07Javier Aguirre, Memo Ochoa and Gilberto...
Read moreDetailsAnthropic accuses Chinese rival Alibaba of illegally extracting AI capabilities
The company alleged that Alibaba used fraudulent accounts to access data from its Claude AI model.
Read moreDetailsIndependent MPs launch new Australian centrist party
Zali Steggall and Allegra Spender say Community Strong Australia will offer citizens “sanity rather than rage”.
Read moreDetailsICE raids are over, but some Minnesotans say they still live in fear
Six months after the Trump administration ended its immigration crackdown, Minneapolis is still feeling the effects.
Read moreDetailsThe largest scorpion in the world lived 415 million years ago
A prehistoric scorpion was the largest that ever existed, and it may have preyed on both land and freshwater species.
Read moreDetailsChris Eubank Jr announces ring return plan: ‘It’s a great position’
After suffering a one-sided defeat last time out, some British fight fans were expecting to hang up their gloves, but...
Read moreDetails
Recent News
Trusted news coverage delivering accurate reporting, breaking headlines, and insightful analysis on global events, business, politics, and tech.